HUYABIO International
Rick Witte has a wealth of experience in pharmaceutical development and manufacturing, specifically in anti-sense microRNA formulations and siRNA drug products. With a background in materials science and biomedical engineering, Rick has held various leadership positions at companies such as HUYA Bioscience International, Regulus Therapeutics, and Isis Pharmaceuticals. Their expertise includes managing drug product development, solid-lipid nanoparticle formulation development, and process development for clinical trials.
HUYABIO International
HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.